Baidu
map

Nature:白介素-35 (IL-35)的负免疫调控作用

2014-05-04 Nature中文网 Nature中文网

这项研究发现,产生白介素-35 (IL-35)的B细胞是新颖的负免疫调控因子。具有不能产生IL-35 的B细胞的小鼠被证明易患诱导的自免疫疾病,同时对沙门氏菌感染的抵抗力增强。这一发现表明,IL-35 由B细胞的生成是自免疫疾病和传染病的一个潜在治疗目标。原始出处:Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg

这项研究发现,产生白介素-35 (IL-35)的B细胞是新颖的负免疫调控因子。具有不能产生IL-35 的B细胞的小鼠被证明易患诱导的自免疫疾病,同时对沙门氏菌感染的抵抗力增强。这一发现表明,IL-35 由B细胞的生成是自免疫疾病和传染病的一个潜在治疗目标。

原始出处:
Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, Li R, Jouneau L, Boudinot P, Wilantri S, Sakwa I, Miyazaki Y, Leech MD, McPherson RC, Wirtz S, Neurath M, Hoehlig K, Meinl E, Grützkau A, Grün JR, Horn K, Kühl AA, Dörner T, Bar-Or A, Kaufmann SH, Anderton SM, Fillatreau S.IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.Nature. 2014 Mar 20;507(7492):366-70.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036918, encodeId=e1b120369186c, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 05:07:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880041, encodeId=3a7e1880041d4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 11 22:07:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372096, encodeId=0e1413e2096c2, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599282, encodeId=00191599282ac, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
    2015-03-06 qblt
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036918, encodeId=e1b120369186c, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 05:07:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880041, encodeId=3a7e1880041d4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 11 22:07:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372096, encodeId=0e1413e2096c2, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599282, encodeId=00191599282ac, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
    2014-06-11 heli0118
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036918, encodeId=e1b120369186c, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 05:07:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880041, encodeId=3a7e1880041d4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 11 22:07:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372096, encodeId=0e1413e2096c2, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599282, encodeId=00191599282ac, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036918, encodeId=e1b120369186c, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 05:07:00 CST 2015, time=2015-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880041, encodeId=3a7e1880041d4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jun 11 22:07:00 CST 2014, time=2014-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372096, encodeId=0e1413e2096c2, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599282, encodeId=00191599282ac, content=<a href='/topic/show?id=bfa7291e596' target=_blank style='color:#2F92EE;'>#免疫调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29175, encryptionId=bfa7291e596, topicName=免疫调控)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f5018689307, createdName=yangcx0921, createdTime=Tue May 06 06:07:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]

相关资讯

Cell:陈东戎等发现耐药菌抗药“开关”


图片来源:Cell

复旦大学上海医学院英国籍全职***特聘教授、复旦大学生物医学研究院研究员、复旦大学基础医学院教育部分子医学重点实验室教授AlastairMurchie和研究员陈东戎带领的课题组,历经3年多时间,在耐药性病原菌中首次发现了一种对抗氨基糖苷类抗生素药物的新型“核糖开关”,该“开关”对控制此类抗生素的耐药性有重大作用。该成果符合开发新型靶标药物的要求,具有极大的临床实用潜力。1月18日,《细胞》刊发了这一重大发现。

随着抗生素的广泛应用,致病菌的耐药性日益严重,因此找到“耐药性如何形成的新机制”已成为各国科学家面临的共同难题。该课题组此次发现耐药菌对抗氨基糖苷类抗生素药物的新型“核糖开关”,有望攻克此类药物带来的耐药难题。以卡那霉素、链霉素、庆大霉素和新霉素等为代表的氨

PNAS:中国频繁使用抗生素可能促进对所有主要类型抗生素的耐药性

PNAS一项研究提出,中国动物养殖厂不加监管地使用抗生素可能促进多种耐抗生素基因的大量出现并释放到环境中去。中国是全世界最大的抗生素制造者和消费者;然而,在中国使用抗生素治疗牲畜疾病和促进动物生长的做法并没有得到监管。Yong-Guan Zhu、James M. Tiedje及其同事确定了中国的3个大型商业养猪场的动物粪便、堆肥和土壤中的超过100种抗生素耐药基因的不同类型和浓度。这组作者报告说,

PNAS:肠道微生物群信号可能调控血压

一项研究发现,通过对两个主要的短链脂肪酸(SCFAs)受体——嗅觉受体78 (Olfr78)和Gpr41起作用,肠道微生物群产生的短链脂肪酸(SCFAs)可能在调控血压方面起到作用。 Jennifer L. Pluznick及其同事发现,Olfr78在肾脏中表达,并且会响应短链脂肪酸(SCFAs),特别是响应丙酸盐,而介导肾素分泌。当给小鼠提供丙酸盐的时候,它们的血压会出现幅度大而迅速的基于剂量

PLoS Comput Biol:科学家开发出研究丙肝病毒传播的新方法

近日,刊登在国际杂志PLoS Computational Biology上的一篇研究报告中,来自牛津大学的研究者表示,对静脉注射感染丙肝的患者进行早期诊断和相应的疗法可以有效抑制丙肝病毒的多次传播。 研究者Gkikas Magiorkinis说,这项研究中我们首次揭示了丙肝病毒之所以具有超级传播性是由于进行静脉注射药物的人所引发的。我们希望可以扩大对静脉注射药物个体的早期诊断和抗病毒的治疗,从而

Science:研究者或可构建一种更好的HIV疫苗

刊登在近日的国际杂志Science上的一篇研究报告中,来自国外的研究人员设计了一种免疫原,它代表了朝着制造一种可在人体内释放对抗HIV-1的广谱中和抗体疫苗所迈出的重要的第一步。 Joseph Jardine及其同事对近些年来在世界各地的病人体内分离出的这种高度有效的广谱中和抗体——它对HIV-1的gp120包膜蛋白具有特异性——进行了研究。 研究人员接着想出了一种方法来设计可与这些高度变异的

研究称英国30多年后炎热发病致死人数倍增

全球变暖正给人们的健康带来不利影响。英国的一项新研究称,到2050年,因炎热导致发病死亡的英国人将增加两倍多,其中老年人面临的“热病”风险最高。 英国英格兰公共卫生局等机构研究人员在英国新一期《流行病和公共卫生杂志》上报告说,他们对1993年至2006年间英国的天气情况和死亡率进行了研究,重点分析气温变化与相关疾病发病之间的关系。 结果显示,照目前的全球变暖和人口增加趋势,到2020年,英国因

Baidu
map
Baidu
map
Baidu
map